Key result
Escherichia coli lipopolysaccharide (100-300 microg/ml) dose- and time-dependently inhibited platelet aggregation in human platelets stimulated by agonists.
Population
Human platelets
Design
Preclinical
Follow-up
10-60 minutes
Authors
Loading...
May contribute to sepsis-related bleeding; hypothesis-generating for platelet pathway modulation in humans.
Escherichia coli lipopolysaccharide inhibits platelet aggregation via conformational changes in the platelet membrane and activation of the NO/cGMP pathway, which may contribute to bleeding diathesis in sepsis.
Sheu et al. (1998) studied this question. Escherichia coli lipopolysaccharide (LPS) was evaluated on platelet aggregation. Escherichia coli lipopolysaccharide (100-300 microg/ml) dose- and time-dependently inhibited platelet aggregation in human platelets stimulated by agonists.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: